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Abstract
On exposure to sunlight, urocanic acid (UCA) in the skin is converted from trans to the cis form and distributed systemically
where it confers systemic immunosuppression. The aim of this study was to determine if administration of cis-UCA would be
effective in attenuating colitis and the possible role of IL-10. Colitis was induced in 129/SvEv mice by administering 5%
dextran sodium sulfate (DSS) for 7 days in drinking water. During this period mice received daily subcutaneously injections
of cis-UCA or vehicle. To examine a role for IL-10, 129/SvEv IL-10
2/2 mice were injected for 24 days with cis-UCA or vehicle.
Clinical disease was assessed by measurement of body weight, stool consistency, and presence of blood. At sacrifice, colonic
tissue was collected for histology and measurement of myeloperoxidase and cytokines. Splenocytes were analyzed for
CD4+CD25+FoxP3+ T-regulatory cells via flow cytometry. Murine bone-marrow derived antigen-presenting cells were
treated with lipopolysaccharide (LPS) 6 UCA and cytokine secretion measured. Our results demonstrated that cis-UCA at a
dose of 50 mg was effective in ameliorating DSS-induced colitis as evidenced by reduced weight loss and attenuated
changes in colon weight/length. This protection was associated with reduced colonic expression of CXCL1, an increased
expression of IL-17A and a significant preservation of splenic CD4+CD25+FoxP3+ T-regulatory cells. cis-UCA decreased LPS
induced CXCL1, but not TNFa secretion, from antigen-presenting cells in vitro. UCA reduced colonic levels of IFNc in
IL-10
2/2 mice but did not attenuate colitis. In conclusion, this study demonstrates that cis-urocanic acid is effective in
reducing the severity of colitis in a chemically-induced mouse model, indicating that pathways induced by ultraviolet
radiation to the skin can influence distal sites of inflammation. This provides further evidence for a possible role for sunlight
exposure in modulating inflammatory disorders.
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Introduction
Inflammatory bowel diseases (IBD), consisting of Crohn’s
disease (CD) and ulcerative colitis (UC), are chronic inflammatory
conditions of the gut believed to occur in genetically predisposed
individuals who are exposed to unknown environmental and
microbial triggers [1,2,3,4]. Epidemiological evidence suggests that
ultraviolet radiation may play a protective role in several
autoimmune disorders, including multiple sclerosis, rheumatoid
arthritis, and inflammatory bowel disease [5]. The geographical
distribution of these diseases, including IBD, inversely correlates
with exposure to ultraviolet radiation. There is a North-South
gradient in IBD incidence in Europe and North America, where
both CD and UC increase in concurrence with latitude increases
[6,7,8].
One well studied mechanism by which sunlight exposure
conveys beneficial effects involves the synthesis of vitamin D in
the skin, which has been subsequently shown to have immuno-
modulatory properties by downregulating Th1 driven immune
responses[9]. Another mechanism by which sunlight conveys
immunomodulatory properties was reported by De Fabo and
Noonan when they generated an action spectrum to determine
how the transduction of UV radiation into a biochemical signal
occurs [10]. It was determined that narrow-band UV radiation
between the wavelengths of 250 and 320 nm photoisomerizes a
photoreceptor known as trans-urocanic acid into cis-urocanic acid
in the stratum corneum of the epidermis[10]. Several other groups
have reported that upon photoisomerization, cis-urocanic acid (cis-
UCA) is distributed systemically, where it has been shown to
convey both local and systemic immunosuppression [11]. cis-UCA
has shown effectiveness in down-regulating hypersensitivity
reactions, decreasing the presentation of tumor antigen by
Langerhans cells, and suppressing cell mediated immuni-
ty[12,13,14]. There are numerous pathways in which cis-UCA
can mediate effects on the immune system as well as multiple
cellular targets including neutrophils, monocytes, keratinocytes, T-
cells and epithelial cells[11,15,16,17]. cis-UCA has been shown to
increase IL-10 secretion by CD4+ T-cells in vitro and ultraviolet-
mediated tolerance and suppression of contact hypersensitivity and
delayed-type hypersensitivity have been shown to be mediated by
IL-10 secreting T-regulatory cells [18,19,20]. In primary human
keratinocytes, cis-UCA has been shown to upregulate expression of
prostaglandin-endoperoxide synthase-2 and cause increased se-
cretion of PGE2; this can potently activate NF-kB resulting in the
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IL-8 [21]. Together, this data indicates that cis-UCA is a
pleiotropic molecule with numerous systemic effects.
The aim of this study was to determine if administration of cis-
UCA subcutaneously would suppress inflammation in a distal site
such as the colon. We hypothesized that the immunomodulatory
effects of cis-UCA would result in an attenuation of colitis due to its
documented ability to decrease inflammatory responses in the skin.
In concordance with this hypothesis, our findings demonstrate that
cis-UCA, administered via the skin, is capable of modulating
inflammatory responses in the colon during chemically-induced
colitis resulting in attenuated colonic inflammation.
Materials and Methods
Animals and induction of colitis
For all animal experiments 8–12 week old homozygous IL-10
gene-deficient mice (IL-10
2/2), generated on a 129 Sv/Ev
background and wild-type 129 Sv/Ev controls were used. Animals
were housed under specific pathogen-free conditions and allowed
free access to regular water and food. In wild-type mice, acute
colitis was induced by the administration of dextran sodium sulfate
(DSS) (M.W.=36,000–50,000, MP Biomedicals) at a concentra-
tion of 5% weight per volume in regular drinking water for 7 days.
Daily weights, the presence or absence of blood, and stool
consistencies were recorded. In DSS experiments mice were
injected daily subcutaneously along the dorsal axis with either 5 or
50 mg cis-UCA or vehicle (PBS). IL-10
2/2 mice develop a chronic
colitis over several weeks following weaning that is characterized
by a patchy transmural inflammation limited to the colon [22]. In
order to determine if cis-UCA would attenuate the development of
colitis in this model, IL-10
2/2 mice were injected every second
day for 24 days subcutaneously along the dorsal axis with either 5
or 50 mg cis-UCA or vehicle control (PBS). All animals were
sacrificed via cervical dislocation, and the entire large intestine and
spleens were removed. DSS experiments were repeated three
times with 4–6 mice per group. cis-UCA treatment of IL-102/2
mice was carried out in groups of 5–6 mice. All experiments were
approved by the University of Alberta Animal Care and Use
committee for health sciences according to Protocol #138.
Cis-urocanic acid
Commercially available cis-urocanic acid (Sigma Chemical, St.
Louis, MO) was dissolved at a concentration of 1 mg/ml in sterile
PBS. All aliquots were stored in the dark to ensure their stability.
Histological injury and disease activity grading
The large intestine was removed free of fatty tissue and
mesenteric lymph nodes. Entire colon length was measured from
the proximal colon to the rectum. The entire colon was flushed
with ice cold PBS containing penicillin/streptomycin and
gentamycin. Two colonic segments were frozen at 220uC and
saved for sonication to analyze cytokine and myeloperoxidase
levels. A third segment was fixed in 10% neutral buffered formalin
and paraffin-embedded. Paraffin embedded tissue sections were
cut 5 mm thick and stained with Hematoxylin and Eosin (H&E) for
general histology. Disease activity scores for DSS treated mice
were based on the cumulative scores (0–10) from 3 different
parameters: Stool consistency (0=normal, 1=soft but still formed,
2=very soft, 3=diarrhea), presence of blood in stool (0=negative
heamocccult, 1=positive hemoccult, 2=blood traces visible in
stool, 3=rectal bleeding) and histological changes (0–4). Histo-
logical scoring was performed by two different pathologists in a
blinded manner. Criteria for histological scoring of DSS treated
mice was based on the following parameters - no evidence of
inflammation (score=0); low level of inflammation with scattered
infiltrating mononuclear cells and neutrophils (score=1); moder-
ate inflammation with multiple foci of neutrophils (score=2); high
degree of inflammation with increased vascular density and
marked wall thickening (score=3); maximal severity of inflamma-
tion with transmural leukocyte infiltration and loss of goblet cells
accompanied by ulceration (score=4). Histological scoring of
intestinal inflammation for IL-102/2 mice was performed using
the scheme previously defined by Madsen et al. [22]. Briefly,
histological grades (ranging from 0–10) represent the sum of four
scoring criteria: mucosal ulceration (0–3), epithelial hyperplasia (0–
3), lamina propria mononuclear infiltration (0–2), and lamina
propria neutrophilic infiltration (0–2).
Cytokine and myeloperoxidase measurement
At sacrifice, a section of colon was removed, weighed, and
immediately flash-frozen. Samples were kept at 270 C until
analysis by ELISA. The following DuoSetH ELISA Development
System antibody sets from R&D Systems (Minneapolis, MN) were
used: mouse IL-10 (DY417), mouse IL-6 (DY406), mouse IFN-c
(DY485), mouse TNFa (DY410), mouse CXCL1/KC (DY453),
mouse IL-23 (DY1887), and human CXCL8/IL-8 (DY208).
Mouse IL-17A was measured using the ELISA Ready-Set-Go
antibody kit from eBioscience (cat#88-7371). Levels of myeloper-
oxidase (MPO) in colonic tissue were measured using an ELISA kit
(Cell Sciences, Canton, Massachusetts, USA).
Preparation and activation of murine spleen cells
Spleens were removed aseptically from mice and teased into
single cell suspensions in IMag buffer (BD Biosciences) in sterile
Petri dishes on ice. The cell suspension was centrifuged at 200 g
for 10 min and the cell pellet resuspended in lysis medium (1
volume of 0.17 M Tris, pH 7.6, 9 volumes of 0.16 M NH4Cl) to
remove red blood cells and repelleted. Supernatants were
aspirated and pellets resuspended in 1 ml IMag buffer. Cell
numbers were determined by coulter counter. 1610
6 total
splenocytes were stained for CD4, CD25, FoxP3 and IL-10 and
analyzed via flow cytometry. Cells positive for CD4 and CD25
were gated and analyzed for their expression of FoxP3, IL-10, and
IL-17A. Cell numbers are expressed as percentages of total cells.
Dot plots and histograms were obtained using FCS express version
3 research edition.
Generation of bone marrow-derived antigen-presenting
cells (BM-APCs)
Bone marrow was harvested and pooled from 3 wild-type 129
Sv/Ev mice. Femurs of mice were removed, cleaned of all tissue
and rinsed in 70% ethanol on ice for 2–5 min. Femurs were
flushed vigorously with media containing RPMI 1640, 100 U/ml
penicillin, 100 mg/ml streptomycin, 2 mM L-Glutamine, 50 mM
mercaptoethanol, 10% heat inactivated FBS. Cells were seeded in
100 mm sterile Petri dishes at a density of 2610
6 cells in media
containing 20 ng/ml rmGM-CSF (PeproTech, Rocky Hill, NJ)
and 5 ng/ml rmIL-4 (PeproTech, Rocky Hill, NJ). Cells were
maintained at 37uC in a 5% CO2 atmosphere. Cultures were re-
fed after 3 days with fresh media. On days 6 and 8, half of the cell
supernatant was collected, centrifuged at 1100 rpm for 5 minutes
and resuspended in media containing rmGM-CSF and rmIL-4
and returned to the Petri dish. On day 10 cells were used for
experiments. Experiments utilizing BM-APCs were carried out in
triplicate using bone marrow pooled from 3 wild-type 129 Sv/Ev
mice for each experiment. Cells were plated at a density of 1610
6
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PLoS ONE | www.plosone.org 3 October 2010 | Volume 5 | Issue 10 | e13676Figure 2. Effect of cis-UCA and DSS on tissue cytokines. 129Sv/Ev mice were treated with 5% DSS for 7 days to induce acute colitis. Beginning
on the first day of DSS administration mice were injected subcutaneously along the dorsal axis daily for 7 days with 50 mg cis-UCA or vehicle (PBS).
Colonic tissue was ultrasonicated and supernatants were analyzed for total levels of cytokines. cis-UCA and DSS had no significant effects on tissue
levels of IL-10 (A). DSS treated mice had increased levels of IL-17, and these were further increased in mice treated with cis-UCA (50 mg) (B). DSS
treated mice had increased levels of colonic IL-6 (C) and IL-23 (D) and these values were not altered by cis-UCA (50 mg) n=5–25 for all measurements.
a: p,0.01 DSS+PBS compared with control PBS, control UCA (50 mg), and DSS+UCA (50 mg). b: p,0.01 DSS+UCA (50 mg) compared with control PBS
and control UCA (50 mg). c: p,0.01 DSS+PBS compared with control PBS, and control UCA (50 mg). d: p,0.01 DSS+UCA (50 mg) compared with
control PBS, and control UCA (50 mg). e: p,0.01 DSS+PBS compared with control PBS, and control UCA (50 mg). f: p,0.01 DSS+UCA (50 mg)
compared with control PBS, and control UCA (50 mg).
doi:10.1371/journal.pone.0013676.g002
Figure 1. cis-UCA (50 mg) ameliorates dextran sodium sulfate (DSS)-induced disease in 129Sv/Ev mice. 129Sv/Ev mice were treated with
5% DSS for 7 days to induce acute colitis. Beginning on the first day of DSS administration mice were injected subcutaneously along the dorsal axis
daily for 7 days with either 5 or 50 mg cis-UCA, or vehicle (PBS). Measurements were taken on Day 7. DSS treatment induced weight loss in mice, and
this was attenuated by treatment with cis-UCA (50 mg). Mice receiving cis-UCA and DSS at the low dose (5 mg) had a transient increased weight loss
compared with mice receiving the high dose of cis-UCA and DSS at days 1 and 2 (A). Total colonic disease activity score (DIA) was reduced by cis-UCA
(50 mg) treatment (B). DSS treatment increased the colonic weight/length ratio, and this was prevented by treatment with cis-UCA (50 mg). Mice
receiving the low dose of cis-UCA had a reduced weight/length ratio compared with PBS-treated and cis-UCA (50 mg) mice (C). DSS treatment
increased levels of the chemokine, CXCL1, in colonic tissue, and this was attenuated by cis-UCA (50 mg) treatment (D). Total tissue levels of
myeloperoxidase (MPO) were significantly increased in cis-UCA (5 mg) + DSS treated mice (E). n=5–25 mice for all measurements. {:p ,0.05 UCA
(50 mg) compared with UCA (5 mg); *: p,0.05 UCA (50 mg) compared with PBS. a: p,0.01 UCA (50 mg) compared with PBS; b: p,0.01 Control UCA
(5 mg) compared with control PBS, control UCA (50 mg), PBS+DSS, DSS+UCA (5 mg), and DSS+UCA (50 mg). c: p,0.05 PBS+DSS compared with control
PBS, control UCA (5 mg), control UCA (50 mg), and DSS+UCA (50 mg). d: p,0.01 DSS+PBS compared with control PBS, control UCA (5 mg), control UCA
(50 mg), and DSS+UCA (50 mg). e: p,0.01 DSS+UCA (5 mg) compared with control PBS, control UCA (5 mg), control UCA (50 mg), and DSS+UCA
(50 mg). f: p,0.05 DSS+UCA(50 mg) compared with control PBS and control UCA (50 mg). g: p,0.05 DSS+UCA (5 mg) compared to control UCA (5 mg)
and DSS+UCA (50 mg).
doi:10.1371/journal.pone.0013676.g001
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treatment performed in triplicate over 3 separate experiments.
Statistical analysis
Data are expressed as means 6 SEM. Data were tested for
normality of distribution and analyses performed using the
statistical software SigmaStat (Jandel Corporation, San Rafael,
CA). Differences between means were evaluated using analysis of
variance or paired t-tests where appropriate. Specific differences
were tested using the Student-Newman-Keuls test.
Results
cis-UCA attenuates acute DSS-induced colitis
Following 7 days of DSS administration, mice receiving the
high dose of cis-UCA (50 mg) lost significantly less weight
compared with those mice receiving vehicle and the low dose
of cis-UCA (5 mg) (Fig. 1A). In addition, mice receiving the high
dose of cis-UCA had lower overall disease activity score
compared to values seen in control mice (Fig. 1B). Following 7
days of DSS administration, mice receiving cis-UCA (50 mg) had
a stool consistency score of 2.260.7 and a blood score of
2.060.87 (N=22) while control mice receiving PBS had a stool
consistency score of 2.860.4 and a blood score of 2.760.4
(N=25). Mice receiving high dose cis-UCA (50 mg) also
maintained colonic weight to length ratios to values seen in
control mice (Fig. 1C). These values, combined with the weight
change score, resulted in a significant attenuation of disease score
in the mice treated with cis-UCA at the high dose of 50 mg
(Fig. 1B). Interestingly, in the absence of DSS, mice administered
the low dose of cis-UCA (5 mg) had a decreased colon weight
to length ratio compared to both PBS control and the high dose
cis-UCA (50 mg) (Fig. 1C). DSS treatment resulted in increased
colonic levels of the neutrophil chemokine, CXCL1 (Fig. 1D)
Mice receiving the high dose of cis-UCA had reduced levels of
CXCL1 (Fig. 1D). Mice receiving the low dose of cis-UCA had
similar levels of MPO (Fig. 1E) and CXCL1 to the PBS-treated
DSS group.
Effect of cis-UCA on colonic cytokines
In the skin cis-UCA has been shown to modulate various
cytokine responses including IL-10, TNFa, IL-6 and IL-8
secretion [18,19,20,21]. However, whether administration of cis-
UCA via the skin has effects in the gut has not been determined.
We examined levels of IL-6, IL-10, IL-17A, and IL-23 in the
colons following 7 days of cis-UCA treatment, and also following
the induction of colitis. Treatment of mice with cis-UCA in the
absence of DSS resulted in no significant change in levels of
colonic IL-10 (Fig. 2A), IL-17A (Fig. 2B), IL-6 (Fig. 2C), and IL-23
(Fig. 2D). DSS treatment resulted in a significant increase in levels
of IL-17A, IL-6, and IL-23 in both cis-UCA and PBS treated
groups. Interestingly, in the DSS-treated group, mice receiving the
high dose of cis-UCA had significantly elevated IL-17A levels
compared to mice receiving DSS and PBS (Fig. 2B).
cis-UCA effects on splenocyte TH17 and T regulatory cells
IL-17A is secreted by numerous cell types, including Th17 cells,
cd T cells, NK cells, and neutrophils, and has an important role in
host defence [23]. Due to the increased levels of IL-17A seen in the
colon, we assessed splenocytes to determine if cis-UCA treatment
increased the number of Th17 cells. However, there was no
difference in the amount of Th17 cells in the spleen in any of the
groups (data not shown). In that a balance exists between Th17
cells and the induced FoxP3+ subset of regulatory CD4+CD25+ T
cells, we also examined whether treatment with cis-UCA altered
CD4+CD25+FoxP3+ T-cells in the spleen. Treatment of mice
with cis-UCA (50 ug) did not result in any change in the
percentage of CD4+CD25+FoxP3+ cells as compared with the
control group (Fig. 3C). During acute DSS-colitis, mice receiving
vehicle showed a significant drop in total percentage of
CD4+CD25+FoxP3+ splenocytes, while mice receiving cis-UCA
maintained pre-DSS levels of CD4+CD25+FoxP3+ cells and were
significantly higher than PBS control levels (Fig. 3C). There was a
similar trend towards increased levels of FoxP3+IL-10+ cells in the
DSS-UCA treated group, however this did not reach significance
(Fig. 3D). (p=0.11)
In vitro effects of cis-urocanic acid on bone marrow
derived antigen-presenting cells
To determine if the decreased levels of CXCL1 seen in the
colonic tissue were due to a direct effect of cis-UCA on antigen-
presenting cells we examined if cis-UCA would modulate cytokine
responses to LPS in bone-marrow derived antigen-presenting cells
(BM-APCs). BM-APCs were incubated with cis-UCA for 24 hrs
and TNFa and CXCL1 secretion were measured. As seen in
Figure 4B, cis-UCA alone did not induce TNFa or CXCL1
secretion. LPS stimulation of BM-APCs cells induced cellular
maturation, as evidenced by enhanced TNFa secretion (Fig. 4B).
The presence of cis-UCA did not alter maturation of BM-APCs
cells in response to LPS. However, BM-APCs treated with cis-
UCA either as concurrent or pre-treatment resulted in a significant
(p,0.01) decrease in CXCL1 secretion (Fig. 4C), indicating that
cis-UCA does have a direct modulating effect on antigen-
presenting cell responses to microbial-derived LPS. This response
was however not dose dependent at these concentrations, as a
significant reduction of CXCL1 secretion was observed for all
three doses of cis-UCA tested.
Effect of cis-UCA on chronic intestinal inflammation in
the IL-10
2/2 mouse
Finally, due to the ability of cis-UCA to increase IL-10 secretion
[18], coupled with our observation of a trend towards a cis-UCA-
induced increase in FoxP3+IL-10+ T cells in the DSS studies, we
next carried out a series of experiments in the IL-10
2/2 mouse
model of colitis. This mouse model of colitis differs from the DSS-
induced acute model, in that a patchy, transmural colitis develops
slowly over a period of weeks [22]. We hypothesized that if IL-10
was required for a cis-UCA-induced attenuation of gut inflamma-
tion, we would see no effect with cis-UCA treatment in this model.
Figure 3. Treatment with cis-UCA (50 mg) maintains splenic T-regulatory cell populations. 129Sv/Ev mice were given 5% DSS for 7 days
and treated with cis-UCA (50 mg) or PBS vehicle daily. Spleens from mice were removed on day 7. Total splenocytes were stained for CD4, CD25,
FoxP3 and IL-10 and analyzed via flow cytometry. Cells positive for CD4 and CD25 (A) were gated and analyzed for their expression of FoxP3 (B). DSS
treated mice had reduced levels of CD4+CD25+FoxP3+ cells when cell numbers were expressed as percentage of total cells (C). cis-UCA (50 mg)
treated mice had similar numbers of CD4+CD25+FoxP3+ cells as compared with control mice (D). DSS and cis-UCA (50 mg) treatment did not alter
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2/2 mice were treated by subcutaneous injection along the
dorsal axis with cis-UCA (5 ug or 50 ug) for 24 days. Control IL-
10
2/2 mice received vehicle. As seen in Figure 5, cis-UCA at
either the high or low dose had no significant effect on disease
activity in IL-10
2/2 mice in either histological score (Fig. 5A) or
colon weight to length ratios (Fig. 5B). Furthermore, in contrast to
the effects seen in wild-type mice, cis-UCA treatment had no effect
on colonic tissue homogenate MPO or IL-17A levels (Fig. 5C,D).
However, treatment with the high dose of cis-UCA did
significantly decrease colonic tissue IFN-c levels compared to
treatment with PBS control and low dose cis-UCA during colitis in
IL-10
2/2 mice, suggesting a cis-UCA-induced modulation of T
cell function, even in the absence of IL-10 (Fig. 4E).
Discussion
This study is the first to examine the effects of cis-urocanic
administration in animal models of intestinal inflammation. Here
we demonstrate for the first time that subcutaneous injection of cis-
UCA along the dorsal axis can have several effects on the intestinal
inflammatory response during colitis and can attenuate acute
colonic disease induced by dextran sodium sulfate. In this study,
reduced severity of disease after cis-UCA treatment was associated
with a decrease in the neutrophil chemoattractant CXCL1, and
increased IL-17A in the colon.
Colitis in the DSS model has been shown to be initiated by the
innate immune system since disease development can occur in the
absence of T and B cells [24]. In this model, oral administration of
DSS induces a breakdown in the intestinal epithelial barrier
resulting in contact of the luminal microflora with the network of
immune cells residing in the lamina propria [24]. In our study,
treatment of mice with cis-UCA resulted in attenuation of disease
severity, as evidenced by reduced disease activity score, weight loss
and maintenance of colonic weight/length ratio. This attenuated
disease was associated with a decrease in the neutrophil
chemoattractant CXCL1. Increased neutrophil infiltration into
the crypts and lamina propria with subsequent formation of crypt
abscesses in the bowel wall is one of the hallmarks of ulcerative
colitis [2,25]. However the exact contribution of neutrophils to
disease pathology in IBD as well as animal models of colitis
remains unresolved. Using mice deficient in CXCL1, Shea-
Donohue et al. demonstrated that a lack of neutrophil infiltration
was accompanied by more severe disease compared to wild type
mice [26], while Buanne et al. demonstrated that mice deficient for
the receptor for CXCL1 had reduced neutrophil infiltration and
reduced clinical disease in the DSS model [27]. Our findings of
reduced disease associated with decreased neutrophilic chemoat-
tractant levels in cis-UCA treated mice are consistent with the
findings of Buanne et al [27]. cis-UCA has been shown to directly
alter neutrophilic function by inhibiting the respiratory burst and
generation of extracellular superoxide while maintaining the
ability of neutrophils to generate intracellular superoxide or other
reactive-oxygen species, thus maintaining phagocytic and micro-
bicidal characteristics intact [28]. This would have the effect of
limiting bystander tissue injury due to neutrophilic release of
reactive oxygen species while maintaining host defence through
bacterial clearance.
CXCL1 is produced primarily from macrophages, dendritic cells,
and epithelial cells in the gastrointestinal tract in response to
microbialstimuli.Ourfindingsthatcis-UCAtreatmenthad aneffect
on reducing colonic CXCL1 levels in the presence of DSS could be
attributable either to a direct effect of cis-UCA on specific cell types,
or alternatively, an effect of UCA on colonic barrier function, and a
resultant lack of stimulation of resident intestinal immune cells by
Figure 4. Effect of cis-UCA on lipopolysaccharide (LPS)-induced
cytokine secretion by bone-marrow-derived antigen present-
ing cells (BM-APC). BM-APCs derived from long-bones of 129 Sv/EV
mice (1610
6 cells/ml) were pre-treated for 2 hrs with cis-UCA (5 mg,
50 mg, or 100 mg) and then stimulated with LPS (1 mg/ml). Supernatants
were collected after 24 hrs. Unstimulated BM-APCs were CD11b+,
CD11c+ and F4/802 (A). LPS induced TNFa secretion from BM-APCs and
this was not altered by the presence of cis-UCA (B). LPS also induced
CXCL1 secretion by BM-APCs and this secretion was attenuated by cis-
UCA (C). n=4–13 for all measurements. *: p,0.01 compared with LPS.
doi:10.1371/journal.pone.0013676.g004
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2/2 mice. 129Sv/EV IL-10
2/2 mice were injected subcutaneously along the dorsal axis
every 2 days for 24 days with either 5 or 50 mg cis-UCA, or vehicle (PBS) (n=5–8). Mice were weighed every second day. cis-UCA had no effect on
colonic histological score (A), weight/length ratio (B), MPO levels (C), or IL-17A levels (D). cis-UCA (50 mg) did reduce levels of colonic IFNc in IL-10
2/2
mice as compared with PBS or cis-UCA (5 mg) treated (E). *: p,0.05 UCA (50 mg) compared with PBS or UCA (5 mg).
doi:10.1371/journal.pone.0013676.g005
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UCA directly inhibits an LPS-induced CXCL1 secretion from
antigen-presenting, but not from epithelial cells. We carried out a
series of experiments in HT-29 cultured colonic epithelial cells. HT-
29 epithelial cells were pre-treated with various doses of cis-UCA
and then stimulated with TNFa or LPS. Stimulation of HT-29 cells
withcis-UCA alone for 3 hrs did not alter IL-8secretion and had no
effect on IL-8 secretion in response to TNFa or LPS (data not
shown), suggesting the observed effects in vivo werenot a direct effect
of cis-UCA suppressing chemokine secretion from enterocytes.
However, as we did not measure the effects of cis-UCA on colonic
permeability or bacterial translocation in DSS treated mice, we
cannot exclude the possibility that cis-UCA also had an indirect
effect on CXCL1 secretion by preventing interactions between gut
microbes and lamina propria immune cells.
An interesting finding in this study was the increased levels of
colonic IL-17A in mice treated with cis-UCA. IL-17A is secreted
by numerous cell types, including Th17 cells, cd T cells, NK cells,
and neutrophils [23,29]. IL-17A has a major role in chronic
autoimmune inflammatory diseases, as well as in the innate
immune response to bacterial pathogens [23]. In response to
bacterial infection, the primary cell type that secretes IL-17 in vivo
appears to be the cd T cell subset that is found predominantly in
the gut mucosa [30]. Our finding of increased levels of IL-17A in
gut mucosa, with no effect of Th17 cells in the spleen, suggests that
cis-UCA may be mediating its effects through the cd T cell subset.
Recent studies have demonstrated evidence for a direct role of IL-
17-producing cd T cells, rather than Th17 cells, in the acute
defence against pathogens [31]. Other studies have shown that IL-
17A produced by cd T cells establishes an amplification loop by
acting directly on Th17 cells to induce their IL-17 production and
also indirectly on dendritic cells to increase their IL-23 production
[32]. Our data supports these findings, in that increased levels of
IL-23 were observed in the cis-UCA-treated mice prior to the
onset of colitis. A beneficial role for IL-17A in DSS colitis was also
demonstrated by Ogawa et al [33] who showed that administration
of a IL-17 neutralizing antibody during acute DSS colitis resulted
in aggravated disease with increased neutrophil infiltration.
Further, in the CD45RBhi CD4+ T cell transfer model of colitis,
IL-17A mediated protection, rather than inducing inflammation
[34]. The ability of IL-17A to protect against bacterial infection
and invasion has been linked with its ability to induce
antimicrobial peptides and also to increased neutrophil microbi-
cidal activity [35,36].
Intraepithelial cdT cells act to enhance mucosal protection as
well as having an important role in healing of tissue. Murine
intestinal cd+ T cells have been shown to express TGF-b mRNA,
secrete IL-10, and inhibit cytotoxic T cell responses [37].
Depletion of cd+ T cells during acute phases of inflammation
has confirmed their protective effect, and has provided evidence
for a role for IL-10 secretion from a subset of cd+T cells in
the control of cytotoxic CD8+ T cell expansion [38]. Mice with a
deficiency in IL-10 spontaneously develop chronic colitis charac-
terized by infiltration of lymphocytes, monocytes and neutrophils
[39]. Disease in these mice is conveyed by Th1 associated
cytokines [39]. In this study, administration of cis-UCA to
IL-10
2/2 mice did not ameliorate disease, but did significantly
decrease colonic IFN-c levels. cis-UCA has been shown to increase
IL-10 secretion by CD4+ T-cells in vitro and ultraviolet-mediated
suppression of contact hypersensitivity and delayed-type hyper-
sensitivity have been shown to be mediated by IL-10 secreting T-
regulatory cells [18,19,20]. Thus, the lack of efficacy of cis-UCA in
the IL-10
2/2 mouse suggests the possibility that IL-10 secreting T-
regulatory cells or cd+ T cells may be critical for cis-UCA effects,
and further, that the increased levels of IFNc are not the primary
driver of gut inflammation in this model [40].
In conclusion, this study demonstrates that cis-urocanic acid is
effective in reducing the severity of colitis in a chemically-induced
mouse model, indicating that pathways induced by ultraviolet
radiation to the skin can influence distal sites of inflammation. This
provides further evidence for a possible role for sunlight exposure
in modulating autoimmune inflammatory disorders.
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